We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vaxart Inc | NASDAQ:VXRT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0071 | -0.95% | 0.7419 | 0.73 | 0.7419 | 0.7494 | 0.69 | 0.749 | 2,154,944 | 23:01:31 |
Delaware
|
001-35285
|
59-1212264
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
||
170 Harbor Way, Suite 300, South San Francisco, California
|
94080
|
|||
(Address of principal executive offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common stock, $0.0001 par value
|
VXRT
|
NASDAQ
|
●
|
Article I was amended to provide that the name and address of the Company’s registered agent in the State of Delaware will be as set forth in the Company’s Certificate of Incorporation.
|
●
|
Sections 2 and 3 of Article II were updated to expressly state that the Board of Directors has the authority to postpone, reschedule or cancel a meeting of the Company’s stockholders that had previously been scheduled by the Board of Directors.
|
●
|
Section 8 of Article II was amended to add a provision providing for a ministerial review of the validity of stockholder consents received by the Company.
|
●
|
A new Section 12 was added to Article II to reflect the requirement under Section 231 of the DGCL to appoint an inspector of elections at a stockholder meeting.
|
●
|
A new Section 13 was added to Article II to address the form and manner in which documents and materials required to be delivered to the Company under Article II of the Bylaws are to be provided.
|
●
|
Section 7 of Article III continues to provide that a majority of the directors in office shall be necessary and sufficient to constitute a quorum of the Board, but was amended to confirm that directors representing at least one-third of the total number of directors is required to establish a quorum.
|
●
|
Section 2 of Article VI was amended to replace the provision stating that directors may be removed from office only by the affirmative vote of the holders of 75% in voting power of the outstanding capital stock entitled to vote in the election of directors with a provision stating that, subject to the Certificate of Incorporation and applicable law, directors may be removed with or without cause by the affirmative vote of a majority in voting power of the outstanding stock entitled to vote generally in the election of directors.
|
●
|
A new Article XVIII was added to provide that, unless the Company elects otherwise, the Court of Chancery of the State of Delaware will be the exclusive forum for enumerated types of internal corporate claims, including derivative suits, claims for breach of fiduciary duty, actions under the DGCL, the Certificate of Incorporation or the Bylaws, and actions under the internal affairs doctrine.
|
Exhibit
|
Description
|
|
3.1
|
Vaxart, Inc.
|
|||||||
Dated: April 13, 2021
|
|||||||
By:
|
/s/ ANDREI FLOROIU
|
||||||
Andrei Floroiu
|
|||||||
President and Chief Executive Officer
|
1 Year Vaxart Chart |
1 Month Vaxart Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions